Athira Pharma Inc represents a strong commitment to advancing neuroscience treatments and improving the lives of patients. The company focuses on developing innovative therapies for neurodegenerative diseases, such as Alzheimer's and Parkinson's. Athira Pharma Inc upholds a corporate philosophy centered around patient-centricity and scientific excellence. By leveraging cutting-edge research and technology, the company aims to bring forth breakthrough solutions to address the significant unmet medical needs in the field of neurology. Athira Pharma Inc is dedicated to making a positive impact on the lives of individuals affected by neurological disorders through its values of innovation, collaboration, and compassion.

Athira Pharma Inc is primarily present in the United States of America (USA).

Athira Pharma Inc has achieved significant milestones in its journey. The company has successfully developed innovative therapies for neurological disorders, creating a positive impact in the healthcare industry. Athira Pharma Inc has conducted extensive clinical trials showcasing the efficacy and safety of their groundbreaking treatments. With their dedication to scientific research and collaboration, the company has made remarkable strides in understanding and addressing the unmet medical needs of patients. Athira Pharma Inc's commitment to advancing therapies for brain health is commendable and has garnered attention and recognition from investors and the medical community alike.

Athira Pharma Inc. is a biopharmaceutical company based in Seattle, Washington. Founded in 2011, Athira Pharma focuses on the development of innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. The company is committed to addressing the significant unmet medical needs in the field of neurologic diseases, aiming to improve patients' lives and their overall quality of life. Athira Pharma's research and development efforts are centered around utilizing regenerative biology and restoring the functionality of neural connections. With a dedicated team of scientists and industry professionals, Athira Pharma Inc. continues to expand its pipeline and strive towards advancing novel treatments for neurodegenerative disorders.

The main competitors of Athira Pharma Inc in the market are other companies operating in the pharmaceutical industry, particularly those developing treatments for neurodegenerative diseases. These competitors may include Biogen Inc, Eli Lilly and Company, Novartis AG, and Roche Holding AG.

Athira Pharma Inc is primarily active in the biotechnology industry.

The business model of Athira Pharma Inc focuses on developing innovative therapeutics to treat neurodegenerative diseases. The company aims to address significant unmet medical needs in conditions like Alzheimer's and Parkinson's disease. Athira Pharma utilizes a proprietary technology platform to target the root causes of these diseases and develop potential treatments. By conducting extensive research and clinical trials, Athira Pharma is dedicated to discovering novel solutions that could improve the lives of patients suffering from neurodegenerative disorders. As a biopharmaceutical company, Athira Pharma Inc strives to deliver groundbreaking therapies and contribute to advancements in the field of neuroscience.

KGV za Athira Pharma trenutno ne može biti izračunato.

KUV za Athira Pharma trenutno ne može biti izračunat.

AlleAktien kvalitativni skor za Athira Pharma je 2/10.

Prihod trenutno ne može biti izračunat za Athira Pharma.

Profit trenutno ne može biti izračunat za Athira Pharma.

Athira Pharma Inc is a biopharmaceutical company that focuses on developing therapies for neurodegenerative diseases. The company was founded in 2011 by Dr. Leen Kawas and is headquartered in Seattle, Washington. The business model of Athira Pharma focuses on three main areas: research and development, clinical development, and business information. Research and development focuses on the identification of molecules and drugs that can impact the progression of neurodegenerative diseases such as Alzheimer's, Parkinson's, and others. The company aims to find innovative methods to slow down or even stop these diseases through in-depth research of disease mechanisms and neurology, combined with cutting-edge technologies. Clinical development aims to evaluate the effectiveness of therapies in the early stages of development. The company conducts clinical trials to assess the effectiveness of therapies in improving symptoms and quality of life for patients with neurodegenerative diseases. Additionally, later-stage clinical trials are conducted to assess the safety and efficacy profiles of therapeutics in a larger number of patients. This leads to business information. Athira Pharma collaborates with partners to bring therapies to patients, both in the US and worldwide. The company continuously expands its distribution channels to ensure that therapeutics are easily accessible to patients in clinical practice. Another important aspect of Athira Pharma's business model is collaboration with other life science companies. The company has partnerships with various companies, including Japan Tobacco Inc. and Desitin Arzneimittel GmbH (part of the Dermapharm Group). These partnerships aim to promote joint research and development and integrate Athira Pharma's new technology into a wider range of therapeutic options. By partnering, Athira Pharma can offer new technologies, products, and solutions more quickly, and respond faster to the needs of customers and patients. In summary, Athira Pharma Inc. pursues an innovative business model that focuses on three main areas: research and development, clinical development, and business information. The company aims to improve the lives of people with neurodegenerative diseases and collaborates with partners to bring therapies to patients. The company strives to grow through collaboration with other companies and further promote its research and development efforts.

Athira Pharma isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Athira Pharma trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Athira Pharma je US04746L1044.

WKN od Athira Pharma je A2QCFW.

Oznaka za praćenje akcija kompanije Athira Pharma je ATHA.

U poslednjih 12 meseci, Athira Pharma je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Athira Pharma će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Athira Pharma trenutno iznosi .

Athira Pharma isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Athira Pharma je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Athira Pharma se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Athira Pharma od 22. 9. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 22. 9. 2024..

Isplata poslednje dividende izvršena je 22. 9. 2024..

U godini 2023 kompanija Athira Pharma je isplatila 0 USD kao dividende.

Dividende od Athira Pharma se isplaćuju u USD.